Quarterly report pursuant to Section 13 or 15(d)

EQUITY TRANSACTIONS (Tables)

v3.22.2.2
EQUITY TRANSACTIONS (Tables)
9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
SCHEDULE OF COMMON AND PREFERRED STOCK OUTSTANDING

 

    September 30, 2022     December 31, 2021  
Common Stock     477,610       166,394  
Series A Preferred Stock     438,776,170       501,887,534  
SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS

Inputs used in the valuation models are as follows:

 

2021 Grants
Option value   $ 54.00       to     $ 56.00  
Risk Free Rate     0.90 %     to       1.37 %
Expected Dividend- yield     -       to       -  
Expected Volatility     173.99 %     to       176.04 %
Expected term (years)     5       to       7  
SUMMARY OF STOCK OPTION ACTIVITY

The following is a summary of stock option activity for the nine months ended September 30, 2021 and 2022:

 

    Shares    

Weighted

Average

Exercise

Price

    Weighted
Average Remaining
Term (Years)
 
Outstanding at December 31, 2020     410     $ 1,390.00       6.72  
Granted     54,750       70.00       9.50  
Expired/Cancelled     (25,525 )     70.00        
Outstanding at September 30, 2021     29,635     $ 100.00       9.41  
                         
Exercisable at September 30, 2021     14,802     $ 100.00       9.41  
                         
Outstanding at December 31, 2021     29,635     $ 86.48       9.20  
Granted                  
Outstanding at September 30, 2022     29,635     $ 86.48       8.46  
                         
Exercisable at September 30, 2022     20,510     $ 93.81       8.44  
SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED

The following is a summary of the Company’s non-vested shares for the nine months ended September 30, 2021 and 2022:

 

    Shares    

Weighted

Average Grant

Date Fair Value

 
Non-vested at December 31, 2020     -     $ -  
Granted     54,750       30.00  
Vested     (14,417 )     50.00  
Forfeited     (25,500 )     70.00  
Non-vested at September 30, 2021     14,833     $ 110.00  
                 
Non-vested at December 31, 2021     14,250     $ 60.00  
Vested     (5,125 )     54.56  
Non-vested at September 30, 2022     9,125     $ 55.61  
SCHEDULE OF ANTI-DILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE

The Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been antidilutive:

 

    2022     2021  
    For the Nine Months Ended September 30,  
    2022     2021  
Warrants to purchase common stock (in the money)     56,250       385,033  
Series A Preferred Stock convertible to common stock     438,776       515,874  
Total     495,026       900,907